Oncology Podcasts
Episode 1

Why treat with Xofigo®▼ (radium-223 dichloride)?
Description
Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible metastatic castration-resistant prostate cancer (mCRPC) patients in their clinics.
Speakers:
- Dr Omi Parikh - Consultant Clinical Oncologist, Lancashire Teaching Hospitals NHS Foundation Trust
- Ellie Cradock - Molecular Radiotherapy Manager, University Hospitals Bristol and Weston NHS Foundation Trust
This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.
Download Reflective Learning Guide
Speakers
PP-XOF-GB-0679 | September 2025



